News - Genentech


Current filters:


Popular Filters

20 to 44 of 60 results

Pharmaco-invasive strategy including Metalyse comparable to primary PCI for STEMI patients


New data presented at the American College of Cardiology 62nd Annual Scientific Sessions and Expo demonstrate…

Boehringer IngelheimCardio-vascularGenentechMetalysePharmaceuticalResearchTNKase

Genentech Ph III study of omalizumab shows promise in CIU


Genentech, the US biotech subsidiary of Swiss drug major Roche (ROG: SIX), announced results from a Phase…

BiotechnologyDermatologicalsGenentechNovartisOmalizumabPharmaceuticalRegulationResearchRespiratory and PulmonaryRocheXolair

US FDA approves Roche's late-stage breast cancer drug Kadcyla


The US Food and Drug Administration on Friday approved Kadcyla (ado-trastuzumab emtansine), a new therapy…

BiotechnologyGenentechImmunoGenKadcylaNorth AmericaOncologyPharmaceuticalRegulationRochetrastuzumab emtansine

Italy's antitrust body investigating Roche and Novartis for alleged cartel


The Italian antitrust authority has opened a cartel investigation of Swiss drug majors Novartis (NOVN:…


Genentech enters $111 million drug discovery pact with RQx Pharma


California, USA-based privately-held RQx Pharmaceuticals said yesterday that it has entered into a drug…

BiotechnologyGenentechLicensingRocheRQx Pharmaceuticals

US biotech giants lobbying to block biosimilars, NTY claims


Some of the USA's biggest biotechnology companies are lobbying intensively to limit generic competition…

AmgenBiotechnologyGenentechGenericsNorth AmericaPoliticsRegulation

FDA clears new use for Roche's Avastin and Novartis' Exjade


The US Food and Drug Administration has approved a new use for Swiss drug major Roche's (ROG: SIX) US…

AvastinBiotechnologyExjadeGenentechNorth AmericaNovartisOncologyPharmaceuticalRegulationRoche

San Antonio breast cancer meeting highlights


There was mixed news coming out of the San Antonio Breast Cancer Symposium (SABCS), which concluded on…


Curis in-licenses cancer candidate from Genentech


US drug development firm Curis (Nasdaq: CRIS) that it has licensed from Genentech, a subsidiary of Swiss…


FDA Approves Abraxane for NSCLC and expands indication for Actemra


The US Food and Drug Administration on Friday approved biotech firm Celgene's (Nasdaq: CELG) Abraxane…

AbraxaneActemraAnti-Arthritics/RheumaticsBiotechnologyCelgeneGenentechNorth AmericaOncologyPharmaceuticalRegulationRoche

US oncologists' perceptions of Roche's Perjeta very promising


Swiss drug major Roche (ROG: SIX) and subsidiary Genentech's Perjeta (pertuzumab), which has been available…

afatinibAfinitorBiotechnologyGenentechMarkets & MarketingNorth AmericaOncologyPerjetaPharmaceuticalRoche

Genentech's T-DM1 significantly improved survival for metastatic breast cancer patients


Swiss drug major Roche (ROG: SIX) US subsidiary Genentech has announced updated results from the Phase…

BiotechnologyGenentechOncologyPharmaceuticalRegulationResearchRocheT-DM1trastuzumab emtansine

Roche gains FDA approval for Lucentis in diabetic macular edema


US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX) announced on Friday that…

GenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Genentech gains FDA panel backing for Lucentis to treat DME


US biotech firm Genentech, a subsidiary of Swiss drug major Roche (ROG: SIX), revealed last week that…

BiotechnologyGenentechLucentisNorth AmericaOphthalmicsPharmaceuticalRegulationRoche

Second collaboration in Alzheimer's disease for Genentech and AC Immune


Switzerland-based biopharma company AC Immune said this morning that it has entered into a second exclusive…

AC ImmuneBiotechnologycrenezumabGenentechLicensingNeurologicalPharmaceuticalResearchRoche

FDA backs Roche's personalized breast cancer therapy Perjeta


The US Food and Drug Administration on Friday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech's…

BiotechnologyGenentechNorth AmericaOncologyPerjetapertuzumabPharmaceuticalRegulationRoche

ASCO 2012: "Show me the overall survival data," say analysts


The annual American Society of Clinical Oncology (ASCO) meeting, held this year in Chicago from June…

GenentechJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Genentech links up with Ensemble Thera for macrocyclic drug candidates discovery


Swiss drug major Roche's (ROG: SIX) subsidiary Genentech has initiated a drug discovery collaboration…

BiotechnologyEnsemble TherapeuticsGenentechLicensingResearchRoche

Groundbreaking Alzheimer's prevention trial announced, as US debuts AD program


A collaboration of the US National Institutes of Health (NIH), Banner Alzheimer's Institute (BAI), University…

crenezumabGenentechNeurologicalNorth AmericaPharmaceuticalPoliticsResearchRoche

US retinal therapeutics market buoyant, says F&S


Alarm bells are ringing loud and clear as diabetes has grown to epidemic proportions worldwide, triggering…

AvastinGenentechLucentisMarkets & MarketingNorth AmericaOphthalmicsPharmaceuticalRoche

Roche to file for trastuzumab emtansine this year, on positive Ph III results


Swiss drug major Roche (ROG: SIX) says that top-line results of EMILIA, the first randomized Phase III…


GSK settles with Genentech over ofatumumab patents


UK pharma giant GlaxoSmithKline (LSE: GSK) has agreed a settlement with Genentech, a unit of Roche (ROG:…

ArzerraBiotechnologyGenentechGenmabGlaxoSmithKlineLegalOfatumumab InjectionOncologyPatentsPharmaceuticalRoche

20 to 44 of 60 results

Back to top